These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
270 related items for PubMed ID: 33370300
1. Implementation challenges and opportunities for improved mass treatment uptake for lymphatic filariasis elimination: Perceptions and experiences of community drug distributors of coastal Kenya. Njomo DW, Kimani BW, Kibe LW, Okoyo C, Omondi WP, Sultani HM. PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009012. PubMed ID: 33370300 [Abstract] [Full Text] [Related]
2. The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya. Kusi C, Steinmann P, Merten S. Infect Dis Poverty; 2020 Mar 02; 9(1):22. PubMed ID: 32114985 [Abstract] [Full Text] [Related]
3. How Thailand eliminated lymphatic filariasis as a public health problem. Rojanapanus S, Toothong T, Boondej P, Thammapalo S, Khuanyoung N, Santabutr W, Prempree P, Gopinath D, Ramaiah KD. Infect Dis Poverty; 2019 May 27; 8(1):38. PubMed ID: 31130143 [Abstract] [Full Text] [Related]
4. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. Njomo DW, Kibe LW, Kimani BW, Okoyo C, Omondi WP, Sultani HM. PLoS Negl Trop Dis; 2020 Sep 27; 14(9):e0008499. PubMed ID: 32936792 [Abstract] [Full Text] [Related]
5. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment. Njenga SM, Kanyi H, Okoyo C, Githinji E, Mwatele C, Matendechero SH, Omondi WP, Gitahi PN, Owaga C, Onsongo JK, Gass K. PLoS Negl Trop Dis; 2024 Jul 27; 18(7):e0011942. PubMed ID: 38976718 [Abstract] [Full Text] [Related]
6. Increasing coverage in mass drug administration for lymphatic filariasis elimination in an urban setting: a study of Malindi Town, Kenya. Njomo DW, Mukoko DA, Nyamongo NK, Karanja J. PLoS One; 2014 Jul 27; 9(1):e83413. PubMed ID: 24454703 [Abstract] [Full Text] [Related]
7. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Njenga SM. PLoS One; 2012 Jul 27; 7(11):e48395. PubMed ID: 23185256 [Abstract] [Full Text] [Related]
8. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia. Krentel A, Fischer P, Manoempil P, Supali T, Servais G, Rückert P. Trop Med Int Health; 2006 Nov 27; 11(11):1731-40. PubMed ID: 17054754 [Abstract] [Full Text] [Related]
9. Towards elimination of Lymphatic Filariasis in Kenya: improving advocacy, communication and social mobilization activities for mass drug administration, a qualitative study. Kibe LW, Kimani BW, Okoyo C, Omondi WP, Sultani HM, Njomo DW. Trop Dis Travel Med Vaccines; 2022 Jun 06; 8(1):16. PubMed ID: 35668465 [Abstract] [Full Text] [Related]
16. How community engagement strategies shape participation in mass drug administration programmes for lymphatic filariasis: The case of Luangwa District, Zambia. Silumbwe A, Halwindi H, Zulu JM. PLoS Negl Trop Dis; 2019 Nov 06; 13(11):e0007861. PubMed ID: 31774820 [Abstract] [Full Text] [Related]